Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 4;16(2):e0246291.
doi: 10.1371/journal.pone.0246291. eCollection 2021.

Hypersensitivity reactions to multiple anti-tuberculosis drugs

Hong-Joon Shin  1 , Jin-Sun Chang  1 , Min-Suk Kim  1 , Bo-Gun Koh  1 , Ha-Young Park  1 , Tae-Ok Kim  1 , Chul-Kyu Park  1 , In-Jae Oh  1 , Yu-Il Kim  1 , Sung-Chul Lim  1 , Young-Chul Kim  1 , Young-Il Koh  2 , Yong-Soo Kwon  1
Affiliations

Hypersensitivity reactions to multiple anti-tuberculosis drugs

Hong-Joon Shin et al. PLoS One. .

Abstract

Objective: This study aimed to evaluate hypersensitivity reactions to anti-tuberculosis (TB) drugs.

Methods: We retrospectively compared the clinical manifestations and treatment outcomes of single and multiple drug hypersensitivity reactions (DHRs).

Results: Twenty-eight patients were diagnosed with anti-TB DHRs using oral drug provocation tests. Of these 28 patients, 17 patients (60.7%) had DHRs to a single drug and 11 (39.3%) had multiple DHRs. The median age of patients was 57.5 years (interquartile range [IQR], 39.2-73.2). Of the total patients, 18 patients (64.3%) were men. The median number of anti-TB drugs causing multiple DHRs was 2.0 (IQR 2.0-3.0). Rifampin was the most common drug that caused DHRs in both the single and multiple DHR groups (n = 8 [47.1%] and n = 9 [52.9%], respectively). The treatment success rate was lower in the multiple DHR group than in the single DHR group; however, the difference was not statistically significant (81.8% vs. 94.1%; P = 0.543).

Conclusions: Multiple anti-TB DHRs were common in all patients who experienced DHRs, and rifampin was the most common causative drug. The treatment outcomes appeared to be poorer in patients with multiple DHRs than in those with single DHRs.

PubMed Disclaimer

Conflict of interest statement

NO authors have competing interests

Figures

Fig 1
Fig 1. Study flowchart.
See this image and copyright information in PMC

References

    1. WHO. Guidelines for treatment of durg-susceptible tuberculosis and patient care. Available: http://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.... 2017.
    1. Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112(6):397–406. 10.7326/0003-4819-76-3-112-6-397 - DOI - PubMed
    1. Kwon YS, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, et al. Clinical characteristics and treatment outcomes of tuberculosis in the elderly: a case control study. BMC Infect Dis. 2013;13:121 10.1186/1471-2334-13-121 - DOI - PMC - PubMed
    1. Kwon YS, Kim YH, Song JU, Jeon K, Song J, Ryu YJ, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci. 2014;29(9):1226–31. 10.3346/jkms.2014.29.9.1226 - DOI - PMC - PubMed
    1. Singh A, Prasad R, Balasubramanian V, Gupta N, Gupta P. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clinical Epidemiology and Global Health. 2015;3:S80–S90.

Publication types